BiotechTube
Home/Brenig Therapeutics/Megan McGill, MD, PhD
MM

Megan McGill, MD, PhD

Chief Executive Officer

Brenig Therapeutics

Therapeutic Areas

Neurodegenerative DiseasesParkinson's Disease

Brenig Therapeutics Pipeline

DrugIndicationPhase
BT-267Parkinson's Disease (LRRK2-associated)Phase 1
BT-409Parkinson's Disease & Neuroinflammatory DisordersPreclinical

Leadership Team at Brenig Therapeutics

ID
Iain Dukes, D. Phil.
Chief Business Officer
View full Brenig Therapeutics profile